John Heymach, MD, PhD, MD Anderson Cancer Center

Articles by John Heymach, MD, PhD, MD Anderson Cancer Center

Expert on lung cancer

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

ByJohn Heymach, MD, PhD, MD Anderson Cancer Center

May 19th 2023

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

Latest Updated Articles

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC
May 19th 2023

Trending on OncLive

FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL

The OncFive: Top Oncology Articles for the Week of 9/27/2026

AUA Releases Guideline Amendment for NMIBC

FLORA-2 Updates at World Lung: Biomarker Analysis, Safety Follow-Up, and ctDNA Monitoring

Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer